Clinic Roundup

August 2012
BioWorld Today;8/31/2012, Vol. 23 Issue 170, p8
The article reports on the initiation of a Phase II trial of oral ELND005 by Elan Corp. plc, the licensing partner of Transition Therapeutics Inc., as an adjunctive maintenance treatment of bipolar I disorder patients to delay the time to occurrence of mood episodes.


Related Articles

  • Elan/Biogen Idec: third PML case is hammer blow for Tysabri.  // PharmaWatch: Biotechnology;May 2005, Vol. 4 Issue 5, p5 

    Reports that Elan/Biogen Idec's ongoing safety evaluation of Tysabri has found another death linked to the drug. Reinforcement of Elan's initial decision to suspend trials and marketing of the drug; Side-effects of Tysabri even in monotherapy; Reassessment of the death of a patient in a Tysabri...

  • DIGESTIVE ROUNDUP.  // BioWorld Today;6/2/2009, Vol. 20 Issue 104, p11 

    The article highlights some of the papers presented at the annual Digestive Disease Week conference in Chicago, Illinois in June 2009. A subset analysis of the Phase III ENACT-2 trial of Tysabri by Elan Corp. plc and Biogen Idec has shown an improvement in the health-related quality of life in...

  • Morphine Oral - Elan Corporation: Avinzaâ„¢.  // Drugs in R&D;2002, Vol. 3 Issue 3, p208 

    Adis Comments Elan Corporation is developing an oral, once daily, controlled-release formulation of morphine sulphate (formerly called Morphelanâ„¢) for use in pain management therapy. Elan Corporation has been granted marketing approval by the FDA for Avinzaâ„¢ (morphine sulphate...

  • Elan's New Drug Reduces Severity of Cervical Dystonia.  // Worldwide Biotech;Dec99, Vol. 11 Issue 12, p2 

    Looks at the results of the studies conducted by Elan Pharmaceuticals Inc. of South San Francisco, California on the drug treating cervical dystonia. Evaluation of Elan's Botulinum Toxin Type B Injectable Solution; Phases of the clinical trial; Effectiveness.

  • CLINIC ROUNDUP.  // BioWorld Today;12/27/2007, Vol. 18 Issue 249, p3 

    This section provides updates on clinical trials in the biotechnology industry as of December 27, 2007. AVI BioPharma Inc. dosed the first patient in a proof-of-concept trial of AVI-4658 in Duchennes muscular dystrophy. Sinovac Biotech Ltd. reported positive top-line results from its Phase II...

  • CLINIC ROUNDUP.  // BioWorld Today;7/14/2009, Vol. 20 Issue 133, p4 

    The article presents news briefs on biotechnology. BioMarin Pharmaceutical will start the Phase I/II trial for its n-acetylgalactosamine 6-sulfatase drug. Elan Corp. plc. and Transition Therapeutics Inc. reported that their scyllo-inositol brand was correlated with improved concentrations in...

  • Other News To Note.  // BioWorld International;6/29/2011, Vol. 16 Issue 26, p5 

    The article presents an update on studies about drug development. A Phase IIa study of HinsBet, the fast-acting human insulin of Adocia SAS of France has been launched for patients with Type 1 diabetes. It relates the risk reduction rate achieved by laninamivir octanoate in influenza A and B...

  • AAN ROUNDUP.  // BioWorld Today;4/14/2010, Vol. 21 Issue 71, p8 

    The article offers information on the researches presented at the 62nd American Academy of Neurology annual meeting in Toronto, Ontario. The analyses of clinical trials data on Ampyra of Acorda Therapeutics suggested that the drug was able to improve walking in patients with multiple sclerosis....

  • Transition Slumps as Deaths End Higher Doses in AD Trial.  // BioWorld Today;12/16/2009, Vol. 20 Issue 241, p4 

    The article reports on the decline in the shares of Transition Therapeutics Inc. following disclosure that its Alzheimer's disease drug ELND005 lead to nine deaths, in December 2009. As stated, shares pegged at 3.50 U.S. dollars to close at 4.41 U.S. dollars. Information on the results from the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics